21:00 , Apr 12, 2018 |  BC Innovations  |  Translation in Brief

Viral variant vaccine

A team from Duke-NUS Medical School rapidly developed a live-attenuated Zika vaccine candidate by exploiting genetic errors to identify a strain with high viremia and reduced propagation. The approach could speed development of live vaccines...
17:54 , Nov 1, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: October 2017

New Therapeutic Targets and Biomarkers: October 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October 2017. Therapeutic targets are defined as any protein, gene or other molecule...
13:53 , Oct 31, 2017 |  BC Innovations  |  Distillery Techniques

Assays and screens

TECHNOLOGY: Diagnostic assays An immunochromatography-based assay that detects viral NS1 proteins could aid the rapid differential diagnosis of Zika infection and dengue fever caused by serotypes DENV1-4. The assay utilizes six immunochromatography dipsticks that each contains...
14:07 , Aug 23, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Zika virus Mouse studies suggest a live-attenuated vaccine encoding loss-of-function mutations in Zika NS1 could help treat Zika viral infection. In pregnant mice with Zika infection, the vaccine decreased Zika viral levels in the maternal...
21:34 , Aug 3, 2017 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: July 2017

New Therapeutic Targets and Biomarkers: July 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during July 2017. Therapeutic targets are defined as any protein, gene or other molecule...
23:49 , Jul 19, 2017 |  BC Extra  |  Preclinical News

Vaccines protect against fetal Zika transmission

In a paper published in Cell, researchers showed that two different vaccines restricted Zika virus transmission from a pregnant mother to the fetus and protected against placental damage and fetal demise. The team tested mRNA-1325, which...
01:26 , Jan 6, 2017 |  BC Innovations  |  Product R&D

Viral ambitions

  Meissa Vaccines Inc. is translating studies from an Emory University team into a pair of vaccine platforms to protect specific at-risk subpopulations from infections by two otherwise innocuous viruses, RSV and the common cold. The...
23:09 , Jan 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Rat studies suggest a live attenuated RSV vaccine engineered to stably express the prefusion conformation of RSV F protein could help prevent RSV infection. The vaccine expressed an RSV F protein...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

Seasonal deltaFLU: Phase I/II data

A Phase I/II trial in adults showed that the deltaFLU vaccine was well tolerated and induced immune responses against all 3 vaccine strains. Avir Green Hills Biotechnology AG, Vienna, Austria   Product: Seasonal deltaFLU (formerly...
08:00 , Jan 18, 2010 |  BC Week In Review  |  Clinical News

Seasonal H1N1 deltaFLU: Phase I data

Data from a placebo-controlled Phase I trial in 48 healthy volunteers showed that escalating doses of Avir Green Hills' intranasal seasonal H1N1 deltaFLU vaccine were safe and well tolerated. The vaccine induced immune responses and...